Skip to main content
. 2024 Jan 22;78(6):1732–1744. doi: 10.1093/cid/ciae010

Figure 1.

Figure 1.

Study design. Participants were randomized before RSV season 1 to receive 1 dose of RSV prefusion F protein–based vaccine (RSVPreF3 OA) or placebo. RSVPreF3 OA recipients were re-randomized before RSV season 2 to receive a second RSVPreF3 OA dose (RSV_revaccination group) or placebo (RSV_1dose group). Participants who received placebo pre–season 1 received a second placebo dose pre–season 2. Abbreviations: NH, Northern Hemisphere; RSV, respiratory syncytial virus; SH, Southern Hemisphere.